UBS AM
KROS icon

UBS AM’s Keros Therapeutics KROS Stock Holding History

UBS AM’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Hold
1,366
– – ﹤0.01% 3194
2026
Q1 		$15.1K Buy
1,366
+1,132
+484% +$17.5K ﹤0.01% 3205
2025
Q4 		$4.76K Buy
+234
New +$4.11K ﹤0.01% 2989
2025
Q1 		– Sell
-64,416
Closed -$1.02M – 2673
2024
Q4 		$1.02M Buy
64,416
+13,864
+27% +$720K ﹤0.01% 2352
2024
Q3 		$2.94M Buy
50,552
+2,271
+5% +$112K ﹤0.01% 1831
2024
Q2 		$2.21M Buy
48,281
+31,146
+182% +$1.67M ﹤0.01% 1945
2024
Q1 		$1.13M Hold
17,135
– – ﹤0.01% 1946
2023
Q4 		$681K Buy
17,135
+6,050
+55% +$190K ﹤0.01% 2220
2023
Q3 		$353K Sell
11,085
-6,050
-35% -$226K ﹤0.01% 2394
2023
Q2 		$732K Hold
17,135
– – ﹤0.01% 2149
2023
Q1 		$732K Hold
17,135
– – ﹤0.01% 2149
2022
Q4 		$823K Hold
17,135
– – ﹤0.01% 1951
2022
Q3 		$645K Buy
17,135
+6,050
+55% +$210K ﹤0.01% 2220
2022
Q2 		$306K Buy
11,085
+3,075
+38% +$135K ﹤0.01% 2476
2022
Q1 		$436K Hold
8,010
– – ﹤0.01% 2505
2021
Q4 		$469K Buy
+8,010
New +$399K ﹤0.01% 2587
2021
Q2 		– Sell
-7,000
Closed -$431K – 2769
2021
Q1 		$431K Buy
7,000
+900
+15% +$57K ﹤0.01% 2432
2020
Q4 		$430K Buy
+6,100
New +$384K ﹤0.01% 2339

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS AM's KROS Position: Q2 2026 in Review

UBS AM held its Keros Therapeutics (KROS) position steady in Q2 2026 at 1,366 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

UBS AM first reported a position in KROS in Q4 2020 and has held it in 18 quarters since. The position peaked at $2.94M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • UBS AM held 1,366 shares of Keros Therapeutics worth $14.6K as of Q2 2026.
  • UBS AM left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3194 holding.
  • UBS AM first reported a position in Keros Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • UBS AM's Keros Therapeutics position peaked at $2.94M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.